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Introduction
Bladder cancer (BC) is the second most common
genitourinary tract malignancy worldwide, with
approximately 386,300 new cases and 150,200 deaths
annually.1 Approximately 75% of BCs are non-muscle
invasive (NMIBC) at the time of diagnosis with 70%
presenting as non-invasive papillary carcinoma (pTa), 20%
as tumour invading lamina propria (pT1) and 10% as
carcinoma in situ (CIS) lesion.2 The main problem for pTa
NMIBC is recurrence (seen in up to 80% of patients) and
for pT1 disease and CIS, the main threat is progression (up
to 45%).3 Transurethral resection of bladder tumour
(TURBT) under white-light cystoscopy followed by
intravesical instillation of mitomycin C (MMC) is the
standard of care for new NMIB tumours. The aim of TUBRT
is two-fold, i.e. to clear all macroscopic disease and to
establish the type of tumour and accurate pathologic
stage.4
Initial check cystoscopy should be done at 3 months after
the transurethral resection (TUR) in every patient and
subsequently a risk-stratified approach should be
adopted for the frequency of follow-up based on risk of
recurrence and progression. The overall recurrence rate
following TUR is as high as 70%5 with the greatest risk at
the first (check) cystoscopy traditionally done 3 months
following TUR.
Due to marked tendency to recur and progress, urothelial
cancer (UC) poses significant diagnostic, prognostic and
therapeutic challenges. The accurate prediction of which
patients are going to recur or progress remains a
challenging task. The current study was planned to
determine the rate and predictors of recurrence in NMIBC
on first check cystoscopy.
Patients and Methods
This cross-sectional study was conducted at the Aga Khan
University Hospital (AKUH), Karachi, from April to
November 2014, and comprised all patients >16 years of
age with a suspected newly-diagnosed UC. Patients with
recurrent disease, incomplete resection, absence of
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Abstract
Objective: To determine the frequency and predictors of non-muscle invasive bladder tumour recurrence on first-
check cystoscopy after transurethral resection of bladder tumour.
Methods: This cross-sectional study was conducted at the Aga Khan University Hospital, Karachi, from April to
November 2014, and comprised patients with a suspected newly-diagnosed urothelial cancer. Patients with non-
muscle invasive disease with complete resection of all visible lesions along with deep biopsy from the tumour base
were included. Patients received standard adjuvant intravesical therapy according to their risk stratification and
underwent a white-light check cystoscopy at 3 months to look for tumour recurrence. Association between clinico-
pathological variables and recurrence at first cystoscopy was determined. SPSS 20 was used for data analysis.
Results: The mean age of 84 patients at presentation was 63.3±12.5 years (range: 36-89 years). There were 75(89%)
men and 9(11%) women. On initial transurethral resection, the size of tumour was less than 3cm in 32(38%)
participants and equal to or above 3cm in 52(62%). Single tumour was found in 51(61%) subjects and multiple
tumours in 33(39%). None of the resected tumours was primary carcinoma in situ and 35(42%) tumours were of high
grade. The overall recurrence rate at first cystoscopy was 28(33.3%). Larger tumour, higher grade and tumour
multifocality were factors associated with recurrence at check cystoscopy (p<0.05 each). Patients' age, gender,
smoking status and tumour stage did not correlate with early recurrence (p>0.05 each).
Conclusion: The number, size and grade of the tumour strongly correlated with recurrence at check cystoscopy.
Keywords: Non-muscle invasive bladder cancer, Recurrence, Check cystoscopy, Predictors. (JPMA 66: S-125; 2016)
UROLOGY
detrusor muscle from the specimen, primary/
concomitant CIS, prior / synchronous UC of upper urinary
tract, non-transitional cell tumour or muscle invasive
disease were excluded.
Approval for the studywas obtained from the institutional
ethics review committee. Patient evaluation was done
with clinical history and physical examination along with
urinalysis and cytology and ultrasound of abdomen and
pelvis. Under general or regional anaesthesia a white-
light cystoscopy was done using 22 Fr. Karl Storz
cystoscopic sheath with 30° lens and TURBT was
performed with 26 Fr. continuous flow resectoscope
sheaths. Complete resection of all visible lesions of
bladder (either en bloc/ in toto for small lesions or
piecemeal for larger ones) including a deep biopsy from
the tumour base was done. We did not take routine
random biopsies from normal looking mucosa. All
patients received single intravesical instillation of 40mg of
MMC in recovery room within 2 hours. A bladder diagram
was drawn, documenting the site of tumour.
Only patients with complete resection by experienced
operating surgeon using white-light cystoscopy and
standard resection equipment and histologically proven
new NMIBC were included. The pathological grade was
classified according to 2004 classification of the World
Health Organisation (WHO)/International Society of
Urologic Pathology (ISUP),6 and tumour was staged
according to the 2009 Tumour node metastasis (TNM)
classification system.7
Patients received standard intravesical therapy according
to risk stratification by European Association of Urology
(EAU) guidelines.8 All patients had their first follow-up
white light (check) cystoscopy under general anaesthesia
at 3 months. We collected the clinical and pathological
data including age, gender, smoking status, tumour
characteristics (i.e. size, site, multiplicity, appearance), T
category (Ta/ T1), tumour grade, completeness of
resection, presence or absence of bladder perforation,
post-operative use of intravesical therapy and similar
findings at subsequent follow-up (check) cystoscopy.
A recurrence was defined as the presence of a bladder
tumour detected on first follow-up cystoscopy after initial
TUR, which was confirmed histologically. Data was
analysed on SPSS 20. For numerical variables, mean ±
standard deviation (SD) were calculated, and for
categorical variables, frequency and percentages were
recorded. Student's t-test and chi-square test were
applied to determine significance. Due to the small
sample size, univariate and multivariate logistic
regression analyses with forward progression were done
to determine the association between clinico-
pathological variables and recurrence at first cystoscopy.
The Hosmer-Lemeshow goodness-of-fit test was used to
assess the multivariate logistic regression model fit.
P<0.05 was considered statistically significant.
Results
Of the 129 patients, 84(65.1%) met the inclusion criteria
and were included. Of the 45(34.9%) excluded, 11(24.4%)
had muscle invasive disease, 17(37.8%) had incomplete
resection or biopsy only, 1(2.2%) patient had squamous cell
carcinoma (SCC) and 1(2.2%) had adenocarcinoma, 3(6.7%)
patients missed follow-up at check cystoscopy, and
12(26.7%) patients showed progression in stage (Ta-T1 or
T1-T2) or in grade (low-high). Of the participating subjects,
75(89%) were male and 9(11%) were female. Themean age
at presentation was 63.3±12.5 years (range: 36-89 years).
Besides, 31(37%) subjects were >60 years while 53(63%)
were equal to or aged below 60 years. Moreover, 44(52%)
participants were smokers. Tumour size on initial resection
was less than 3cm in 32(38%) participants and equal to or
above 3cm in 52(62%). Multiple tumours were seen in
33(39%) patients. The grade of tumours at initial resection
was low in 49(58%) and high in 35(42%) (Table-1).
The overall recurrence at first (check) cystoscopy was seen
in 28(33.3%) patients. Uni-variate analysis identified
higher tumour grade (p=0.01), size >3 cm (p=0.01) and
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Table-1: Patients and tumour characteristics.
Variables All patients N (%) Recurrence N (%)
Gender
Male 75 (89%) 24/75 (32%)
Female 9 (11%) 4/9 (44%)
Age groups
<60 yrs 31 (37%) 12/31 (39 %)
>60 yrs 53 (63%) 16/53 (30%)
Smoker
Yes 44 (52%) 18/44 (41%)
No 40 (48%) 10/40 (25%)
Tumour size on initial resection (TUR)
<3 cms 32 (38%) 4/32 (12.5%)
>3 cms 52 (62%) 24/52 (46%)
Stage at initial resection (TUR)
pTa 43 (51%) 12/43 (28 %)
pT1 41 (49%) 16/41 (39%)
Number of tumours at initial resection (TUR)
Single 51 (61%) 10/51 (20%)
>2 33 (39%) 18/33 (54.5%)
Grade of tumours at initial resection (TUR)
Low grade 49 (58%) 10/49 (20%)
High grade 35 (42%) 18/35 (51%)
TUR: Transurethral resection.
multi-focality (p=0.01) as predicting factors for recurrence
at first cystoscopy. Other factors i.e. age, gender and
tumour stage were also evaluated, but none was found to
correlate significantly with tumour recurrence (p>0.05).
Smoking was not found to be a significant factor for
recurrence either (p>0.05). Multivariate analysis showed
that larger tumours (>3cm) had 4.5 greater odds of
recurrence compared to smaller tumours, and higher
grade tumours and multi-focal tumours had 3.4 greater
odds each of recurrence compared to low-grade and
single tumour at check cystoscopy (Table-2).
Discussion
Bladder carcinoma is the most common malignancy of
the urinary tract. In the south Asia, the reported rate of
bladder cancer is estimated to be about 2.1 per 100,000
populations.[9] Pakistan has the highest incidence of
bladder cancer among the south Asian countries likely
attributed to high tobacco use.10 It is the 4th most
commonmalignant tumour inmales, accounting for 5.6%
of all reported cancers in Pakistan with an age-
standardised rate (ASR) of 8.9 per 100,000 individuals.10
Recurrence in UC is defined as the re-appearance of
tumour after complete resection, which could be due to
"field effect" or "re-implantation". Literature suggests that
50-70% NMIBC have recurrence within 5 years and 5-20%
progress to invasive carcinoma.11 Tumour recurrence
could be due to incomplete resection, persistence, re-
growth of residual tumour or new occurrence due to
growth of microscopic lesion or implantation and growth
of tumour cells at the time of TUR. Due to its prognostic
value, after a complete TUR, the first follow-up cystoscopy
is of utmost importance in NMIBC. EAU guidelines
recommend 3 months as the optimal time for first follow-
up cystoscopy. The rate of recurrence on first cystoscopy
also depends upon completeness of initial TUR, skills and
experience of surgeon and intravesical treatment.12 The
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Table-2: Univariate and Multivariate logistic regression analysis of variables' association with recurrence at first (check) cystoscopy.
Variables Check cystoscopy Recurrence frequency Univariate analysis Multivariate analysis
n n (%) OR (95% CI) OR (95% CI)
Age
<60 31 12 (38.7%)
>60 53 16 (30.2%) 0.68 (0.27-1.73)
p-value 0.42
Gender
Male 75 24 (32%)
Female 9 04 (44.4%) 1.70 (0.42-6.90)
p-value 0.46
Smoker
Yes 44 18 (41%)
No 40 10 (25%) 2.07 (0.81-5.28)
p-value 0.12
Stage
Ta 43 12 (28%)
T1 41 16 (39%) 1.65 (0.66-4.13)
p-value 0.28
Grade
Low 49 10 (20.4%)
High 35 18 (51.4%) 4.13 (1.58-10.78) 3.40 (1.19 - 9.78)
p-value 0.01 0.02
Number of tumours at TURBT
Single 51 10 (19.6%)
> 2 33 18 (54.5%) 4.92 (1.86-13.02) 3.42 (1.19 - 9.84)
p-value 0.01 0.02
Size of tumours at TURBT
< 3cm 32 4 (12.5%)
> 3cm 52 24 (46.2%) 6.0 (1.84-19.54) 4.5 (1.26-16.0)
p-value 0.01 0.02
OR: Odds ratio.
CI: Confidence interval.
TURBT: Transurethral resection of bladder tumour.
presence of detrusor muscle is considered a surrogate
marker for the quality of resection.13 The reported
frequency of absence of deep muscle biopsy is ranging
from 30-50%14 with higher risk of residual disease
especially in pT1 tumour and up to 40% tumour
upstaging to pT2.15
We excluded all the patients who did not receive any
adjuvant treatment due to bleeding or suspected bladder
perforation or when the resection was incomplete or in
whom deep muscle biopsy was not present in the
specimen. Surgeons having more than 15 years of
experience performed all the surgeries.
Mariappan et al.16 have shown that experienced surgeons
are more likely to resect detrusor muscle with a lower risk
of early recurrence and absence of detrusor muscle on
biopsy independently predicts a higher risk of early
recurrence. The quality of TUR (which is mostly subjective)
can be measured by determining complete resection,
presence of detrusor muscle and recurrence at the
resection site. Herr et al. in a retrospective study found
residual disease in 31.6% of Ta/Tis tumours and 51.7% of
T1 tumours.17
In a combined analysis of seven European organisations
for research and treatment of cancer (EORTC) randomised
trials (without re-TUR), the early tumour recurrence was
observed in 13.1% (6.7-40%).18 This wide variability in the
recurrence rate at first follow-up (check) cystoscopy
shows that there is a significant difference in the quality of
treatment between different institutions. A positive
recurrence at the time of check cystoscopy significantly
affects the recurrence and progression free survival.19 In
newly diagnosed pTa grade-1 and grade-2 patients,
Fitzpatrick et al. found that patients free of tumour at 3
months had an 80% chance of having no further
recurrences.20
Near 50% of our patients had higher stage (pT1) disease
and 42% had a high-grade disease thus reflecting a higher
chance of recurrence. All the check cystoscopies were
done under general anaesthesia with biopsies taken via a
larger cold cup biopsy forceps to allow a more accurate
diagnosis. A flexible cystoscopy under local anaesthesia
might miss small lesions or surface changes.
An inappropriate procedure can lead to early recurrence
and inaccurate staging of disease and, therefore,
recurrence rate at first follow-up (check) cystoscopy is a
strong predictor of subsequent recurrence21 and possibly
progression to higher grade/ stage disease.22
In a conventional white-light cystoscopy, which is
considered as the gold standard, resections are not
"radical" despite complete removal of all lesions and up to
30-50% of cases can have residual tumour. Various
strategies have been evaluated to improve the tumour
visualisation such as photodynamic diagnosis (PDD)-
assisted cystoscopy and narrow band imaging (NBI), both
of which have better sensitivity than white-light
cystoscopy for detecting bladder cancer, particularly the
smaller papillary and flat lesions.
They can be adapted at the time of initial TURBT and
subsequent cystoscopy. In a randomised phase-3 trial,
Stenzl et al.23 showed that PDD not only improves the
detection of both papillary bladder cancer and CIS, it also
significantly prolongs time to recurrence and randomised
trials with long-term follow-up have shown that this
benefit is also translated in terms of improved bladder
preservation. Long-term follow-up studies have shown
6.8 months longer median time to recurrence with PDD
compared to white-light cystoscopy with 6% lower
recurrence rate.24 Similarly, NBI-assisted cystoscopy or
resection is associated with fewer recurrences and longer
recurrence-free survival compared to white-light
cystoscopy.25
Despite controlling the predictors such as tumour size
and number, grade and stage, in a review of seven
randomised controlled trials of EORTC, Brausi et al.18
detected significant variation in recurrence among
different institutes on first cystoscopy and concluded that
this discrepancy is the result of variability of quality of
resections. He attributed most of these recurrences likely
to be residual disease rather than the real recurrences.
In a previous study, we determined the recurrence and
progression at one year in 92 NMIBC patients who
underwent TURBT and compared their results with
calculated risk according to EORTC risk table.26 Forty four
per cent of patients had tumours larger than 3cm, 38%
had multiple lesions and 8.7% had high-grade disease. At
one-year follow-up, the recurrence rate was 37% with
significant concordance with EORTC prediction. As
compared to that study, a significantly higher proportion
of patients had high-grade disease in the current study.
We did not look at the cost analysis in our patients. The
cost associated with NMIBC is, however, substantially
higher compared to advanced disease due to very high
recurrence rate, intensive surveillance strategies and
expensive treatment.27
EAU guidelines state that the goal of TUR is to make a
correct diagnosis and to remove all visual lesions.
Different techniques have also been introduced in this
regard including modification of resectoscope loop, laser
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techniques, water jet-based enucleation and "en-bloc"
resection to completely remove the tumour without any
incision and scattering hypothesising that this "no touch"
technique should improve the resection and recurrence
rate.28
Holmang et al.29 studied the relationship of first
cystoscopy findings with recurrence and progression
rates in large population based series of patients with
bladder cancer who were followed up for at least 5 years
and found that negative first cystoscopy findings were
associated with significantly decreased recurrence and
progression for all grades and stage Ta and T1 tumours.
Sylvester et al.19 in their meta-analysis found overall
progression of disease in 25.6% of patients with positive
cystoscopy (recurrence) at 3 months compared to only
8.7% progression in patients with negative 3 months
cystoscopy. This confers that the findings of check
cystoscopy are a significant prognostic factor on time to
progression of disease.
Our study is a prospective one, which is the strength as
various biases like cystoscopy findings, and pre-operative
variables are avoided which could be a problem in a
retrospective study. One of the major limitations of our
study is the small number of patients and that the
resection was deemed complete on a subjective
assessment by the operating surgeon on white-light
cystoscopy. However, as a quality measure, we excluded
all those patients in whom the detrusor muscle was
absent in the first specimen and considered it to be a low-
quality initial TUR who subsequently underwent a re-TUR
in 2-6 weeks' time.
Since none of the cases in our series had any residual or
overlooked macroscopic tumour, we assume that the
recurrence is mainly due to tumour cell implantation or
due to aggressive biology of the disease. In view of
excluding the findings, we presume that the factors,
which predict the recurrence at first cystoscopy in NMIBC,
are tumour grade, multifocality and the size of tumour
along with aggressive tumour biology.
Bladder cancer is a significant health problem for Pakistan.
There is paucity of data on NMIBC with poor insight
regarding the rate of recurrence and progression. In order
to establish a better level of evidence, we recommend a
collaborative multi-institutional prospective study in the
future.
Conclusion
A recurrence rate of 33% was found at first check
cystoscopy for NMIBC. The number, size and grade of the
tumour strongly correlated with recurrence at check
cystoscopy. Patients with these tumour characteristics
should be warned of higher probability of recurrence and
possibly progression in the surveillance period.
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